{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-017353","form_type":"8-K","ticker":"SABS","cik":"0001833214","company_name":"SAB Biotherapeutics, Inc.","filed_at":"2023-06-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.001806+00:00","generated_at":"2026-06-14T01:32:51.594122+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"low","headline":"SAB Biotherapeutics holds virtual R&D Day; reviews platform and recent designations","bullets":["Presented portfolio update including recent Breakthrough Therapy and Fast Track designations.","Highlighted programs: influenza, C. diff, type 1 diabetes (SAB-176, SAB-185, SAB-142, SAB-195).","No new financial guidance, clinical data, or material business changes disclosed.","Presentation furnished as Exhibit 99.1 but not text-available; summary based on filing narrative."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-017353","json":"https://secwatch.observer/filing/0001437749-23-017353.json","markdown":"https://secwatch.observer/filing/0001437749-23-017353.md","text":"https://secwatch.observer/filing/0001437749-23-017353.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1833214/000143774923017353/0001437749-23-017353-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1833214/000143774923017353/sabs20230609_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T01:32:51.594122+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}